Elutia Inc (NAS:ELUT)

$ 3.94 -0.21 (-5.06%) Market Cap: 136.18 Mil Enterprise Value: 133.57 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 56/100

Q3 2024 Elutia Inc Earnings Call Transcript
Nov 14, 2024

$3.83 (+2.13%)

Earnings
Q2 2024 Elutia Inc Earnings Call Transcript
Aug 07, 2024

$2.84 (-3.07%)

Earnings
Q4 2023 Elutia Inc Earnings Call Transcript
Mar 07, 2024

$3.59 (+1.70%)

Earnings
Q3 2023 Elutia Inc Earnings Call Transcript
Nov 13, 2023

$1.46 (-0.68%)

Earnings
Elutia Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 27, 2023
Q2 2023 Aziyo Biologics Inc Earnings Call Transcript
Aug 14, 2023

$1.34 (-2.90%)

Earnings
Q1 2023 Aziyo Biologics Inc Earnings Call Transcript
May 10, 2023

$2.47 (+4.22%)

Earnings
Q4 2022 Aziyo Biologics Inc Earnings Call Transcript
Mar 22, 2023

$1.19 (-2.46%)

Earnings
Aziyo Biologics Inc at Cowen Health Care Conference Transcript
Mar 06, 2023
Q3 2022 Aziyo Biologics Inc Earnings Call Transcript
Nov 14, 2022

$8.1 (+1.12%)

Earnings
Q2 2022 Aziyo Biologics Inc Earnings Call Transcript
Aug 11, 2022

$6.45

Earnings
Q1 2022 Aziyo Biologics Inc Earnings Call Transcript
May 09, 2022

$6.42 (-2.73%)

Earnings
Q4 2021 Aziyo Biologics Inc Earnings Call Transcript
Mar 03, 2022

$6 (-10.28%)

Earnings
Q3 2021 Aziyo Biologics Inc Earnings Call Transcript
Nov 09, 2021

$6.2 (-1.59%)

Earnings
Q2 2021 Aziyo Biologics Inc Earnings Call Transcript
Aug 09, 2021

$8.3 (+2.22%)

Earnings
Aziyo Biologics Inc Annual Shareholders Meeting Transcript
Jun 07, 2021
Q1 2021 Aziyo Biologics Inc Earnings Call Transcript
May 04, 2021

$9.51 (-1.55%)

Earnings
Aziyo Biologics Inc at Cowen Healthcare Conference (Virtual) Transcript
Mar 04, 2021
Q4 2020 Aziyo Biologics Inc Earnings Call Transcript
Mar 01, 2021

$15.51 (-2.58%)

Earnings
Q3 2020 Aziyo Biologics Inc Earnings Call Transcript
Nov 19, 2020

$12.28 (-5.47%)

Earnings

Aziyo Biologics Inc at Cowen Health Care Conference Transcript

Mar 06, 2023 / 02:50PM GMT

Release Date Price: $4.23 (+4.14%)

Transcript

Unidentified Analyst

We're happy to have the team from Aziyo Biologics joining us for presentation. We have CEO, Randy mills; and CFO, Matt Ferguson. I will turn it over them now. Thank you.

Randy Mills

Aziyo Biologics, Inc. - President & CEO

Thank you very much. It's a pleasure to be here today. I'm Randy mills, CEO of Aziyo, and actually a cofounder of the company. A company we've been really putting through a pretty significant transformation of late. I will warn you all, that this is the first time I've given this presentation. So we'll just see how it goes. It could be rough, but it might be a lot of fun, too. So let's just get into it.

First, forward-looking statements. I will be making pretty significant forward-looking statements today. So I'll emphasize this that, any and everything that I say in this slide may or may not -- or in this presentation may or may not come true, but everything that I'm going to tell you is current and accurate to the best of my knowledge as I give the presentation today.

Let me start out with a little bit

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.